[1] Polaris Observatory Collaborators. Global prevalence,treatment,and preventionof hepatitis B virus infection in 2016:A modelling study[J]. Lancet Gastroenterol Hepatol,2018,3(6):383-403.
|
[2] SONG LW,LIU PG,LIU CJ,et al. Quantitative hepatitis B coreantibody levels in the natural history of hepatitis B virus infection[J]. Clin Microbiol Infect,2015,21(2):197-203.
|
[3] XU JH,SONG LW,LI N,et al. Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long—term entecavir[J]. J Viral Hepat,2017,24(2):148-154.
|
[4] VISVANATHAN K,DUSHEIKO G,GILES M,et al. Managing HBV in pregnancy. Prevention,prophylaxis,treatment and follow-up:Position paper produced by Australian,UK and New Zealand key opinion leaders[J]. Gut,2016,65(2):340-350.
|
[5] CHEN HL,LIN LH,HU FC,et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV[J]. Gastroenterology,2012,142(4):773-781.
|
[6] ROUSHAN MRH,SAEDI F,SOLEIMANI S,et al. Changes in the anti-HBc profile of infants born to HBV infected mothers from Iran[J]. Vaccine,2016,34(38):4475-4477.
|
[7] ALEXANDER GJ,EDDLESTON AL. Does maternal antibody to core antigen prevent recognition of transplacental transmission of hepatitis B virus infection?[J]Lancet,1986,1(8476):296-297.
|
[8] THOMAS HC,LEVER AM. Has immunology become important to the hepatologist?[J] Progr Liver Dis,1986,8:179-189.
|
[9] CHANG MH,HSU HY,HUANG LM,et al. The role of transplacental hepatitis B core antibody in the mother-to-infant transmission of hepatitis B virus[J]. J Hepatol,1996,24(6):674-679.
|
[10] LEE JH,PAGLIERONIC TG,HOLLAND PV,et al. Chronic hepatitis B virus infection in an HBc antibody-nonreactive blood donor:variant virus or defective immune response?[J]. Hepatology,1992,16(1):24-30.
|
[11] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
[12] ZHOU J,SONG L,ZHAO H,et al. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase[J]. Sci Rep,2017,7(1):2747.
|
[13] FAN R,SUN J,YUAN Q,et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBe Ag seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues[J]. Gut,2016,65(2):313-320.
|
[14] CHI H,LI Z,HANSEN BE,et al. Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy[J]. Clin Gastroenterol Hepatol,2019,17(1):182-191. e1.
|
[15] KUMAR M,SARIN SK,HISSAR S,et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology,2008,134(5):1376-1384.
|
[16] LI J,ZHANG TY,SONG LW,et al. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels[J]. Hepatol Res,2018,48(3):e133-e145.
|
[17] WU Z,DONG X,WANG G,et al. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal[J].J Viral Hepat,2019,26(2):287-296.
|
[18] YUAN Q,SONG LW,LIU CJ,et al. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients[J]. Gut,2013,62(1):182-184.
|
[19] XU JH,SONG LW,LI N,et al. Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir[J]. J Viral Hepat,2017,24(2):148-154.
|
[20] CAI S,LI Z,YU T,et al. Serum hepatitis B core antibody levels predict HBe Ag seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs[J]. Infect Drug Resist,2018,11:469-477.
|
[21] TSENG CH,HSU YC,CHANG CY,et al. Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B[J]. J Formos Med Assoc,2018,117(10):915-921.
|